AG真人官方

Plug Power Inc. (PLUG) Form 4 filing dated 07/03/2025 reports a routine insider purchase.

Director Patrick Joggerst received 13,423 shares of common stock on 07/01/2025 under the company鈥檚 Non-Employee Director Compensation Plan. The transaction is coded 鈥淎鈥� (acquisition) and valued at an indicated $1.49 per share, increasing the director鈥檚 direct holdings to 101,670 shares. No derivative securities were involved.

This filing signals incremental insider alignment with shareholders; however, the dollar value is modest and does not materially change overall ownership structure.

Ligand Pharmaceuticals (LGND) 鈥� Form 4 insider activity

Chief Legal Officer & Secretary Andrew Reardon disclosed the purchase of 233 common shares on 30 Jun 2025 under the company鈥檚 Employee Stock Purchase Plan (Transaction Code J). The shares were acquired at an average price of $91.0775, an outlay of roughly $21,000. Following the transaction, Reardon鈥檚 direct beneficial ownership rose to 32,136 shares. The Form 4 was filed on 2 Jul 2025.

The transaction is routine ESPP participation rather than an open-market buy, so the immediate market impact is limited. Nevertheless, the filing shows continued executive equity accumulation, modestly reinforcing management鈥搒hareholder alignment.

Centene Corporation (CNC) 鈥� Form 4 insider filing

Director Kenneth A. Burdick reported a modest open-market acquisition of 556 Centene common shares on 30 June 2025 (transaction code A). The shares were acquired at a stated price of $0.00, suggesting the issuance relates to compensation or dividend reinvestment rather than a cash purchase. Following the transaction, Burdick鈥檚 direct ownership increases to 367,052.924 shares. He also reports 86,498 indirect shares held through Burdick Family LLC, bringing his aggregated economic interest to roughly 453.6 thousand shares.

The filing also discloses an existing stock option for 10,000 shares with a strike price of $80.57, exercisable from 7 Feb 2025 and expiring 7 Feb 2032. No new derivative transactions were recorded.

While insider purchases are generally viewed as a confidence signal, the 556-share addition represents less than 0.2 % of Burdick鈥檚 current stake and is immaterial to Centene鈥檚 overall float. The transaction therefore carries limited fundamental impact but modestly reinforces management鈥搒hareholder alignment.

Director John Neuman of SeaStar Medical Holding Corporation (ICU) has increased his position in the company through a significant stock purchase on June 24, 2025. The insider acquired 40,000 shares of common stock at a weighted average price of $0.3599 per share, with individual transaction prices ranging from $0.359 to $0.36.

Following this transaction, Neuman's direct ownership has increased to 80,000 shares of the company's common stock. The purchase was reported via Form 4 filing on June 28, 2025, within the required reporting timeline for insider transactions.

Key transaction details:

• Transaction type: Direct purchase of common stock
• Total transaction value: Approximately $14,396
• Position: Director
• Ownership type: Direct ownership

SeaStar Medical Holding Corporation (Nasdaq: ICU) has filed a Rule 424(b)(4) prospectus for a mixed securities offering designed to raise up to $4.0 million in gross proceeds. The company will sell 4,935,385 shares of common stock at $0.65 per share and 1,218,462 pre-funded warrants at $0.6499 each. Every share or pre-funded warrant is bundled with one Series A warrant (5-year term) and one Series B warrant (18-month term), both carrying a $0.65 exercise price. In addition, placement agent H.C. Wainwright will receive 430,769 warrants (exercise price = 125% of the offering price) plus cash fees equal to 7% of gross proceeds, a 1% management fee, and up to $125,950 in expenses.

The structure is best-efforts and has no minimum, meaning funds are immediately available to the company and investors will not receive refunds if demand is weak. Net proceeds before offering expenses are estimated at $3.68 million; actual proceeds may be substantially lower because warrant exercises are not included. The warrants and pre-funded warrants will not be listed, limiting secondary-market liquidity.

SeaStar is both an emerging growth and smaller reporting company. Following a 1-for-25 reverse split effected on 7 June 2024, ICU shares last closed at $0.9763, while listed $11.50 warrants traded at $0.0284. The company remains under a Nasdaq panel exception that expires 22 June 2025; by that date it must regain compliance with the $2.5 million stockholders鈥� equity rule and update Nasdaq on fundraising and 12-month projections. Failure could result in delisting.

Prospective investors should review the extensive Risk Factors section, which highlights dilution, delisting risk, and the absence of an escrow arrangement.

SeaStar Medical Holding Corporation (NASDAQ: ICU) filed an 8-K detailing three material developments that collectively strengthen short-term liquidity but introduce meaningful future dilution.

1. $6.15 million unit offering: On 20 June 2025 the company priced and, on 23 June, closed a best-efforts public offering of 4,935,385 common shares and 1,218,462 pre-funded warrants, each paired with one five-year Series A warrant and one 18-month Series B warrant. The units were sold at $0.65 (or $0.6499 for the pre-funded alternative). In total 12,307,694 new warrants were issued with a $0.65 strike price, while the pre-funded warrants carry a $0.0001 strike. H.C. Wainwright acted as placement agent, receiving a 7 % cash fee, a 1 % management fee, reimbursable expenses and 430,769 placement-agent warrants exercisable at $0.8125 until 2030.

Proceeds & use of funds: Net cash to SeaStar is estimated at $3.39 million after fees. Management believes existing cash plus the raise will fund operations into November 2025. The purchase agreement limits additional share issuances for 60 days and prohibits variable-rate financings for 12 months, reducing short-term overhang risk.

2. Cost-containment actions: Effective 17 June 2025, the board approved a 20 % reduction in CEO, CFO, CMO and director cash compensation, lowering monthly operating expenses by roughly $50,000. Together with earlier liability waivers that eliminated about $1.2 million in unpaid bonuses and fees, the company expects materially lower cash burn.

3. Nasdaq compliance update: Following a March 2025 hearing, SeaStar had until 22 June 2025 to restore stockholders鈥� equity above $2.5 million. Management asserts that the recent capital raise, liability extinguishment, expanding QUELIMMUNE revenues (six customers in Q2) and cost cuts place the company back in compliance with Listing Rule 5550(b).

Investment takeaways:

• The transaction alleviates immediate liquidity risk but extends the fully-diluted share count by up to 13 million shares (including placement-agent warrants).
• Cash runway remains relatively short (鈮� 5 months) and future capital will likely be required once warrant exercises or the $15 million Lincoln Park equity facility are tapped.
• Management compensation cuts signal shareholder alignment and aggressive expense discipline.
• Nasdaq listing status is tentatively secure, removing a key technical overhang.

SeaStar Medical Holding Corp (ICU) has received a formal Notice of Effectiveness from the U.S. Securities and Exchange Commission, confirming that the company鈥檚 Form S-1 registration statement (File No. 333-288065) became effective on June 20 2025 at 12:00 p.m. ET. The effectiveness marks the final regulatory step required before the company may use the registration statement for activities described therein, such as issuing or reselling securities. No additional financial metrics, transaction details, or offering terms were included in this notice.

SeaStar Medical Holding Corporation (NASDAQ: ICU) has filed an S-1/A amendment for a significant securities offering, including:

The offering comprises:

• Up to 5,149,860 shares of common stock with accompanying Series A and B warrants
• Alternative option of 5,149,860 pre-funded warrants with accompanying Series A and B warrants
• 297,035 placement agent warrants
• Total of 15,746,615 shares issuable upon exercise of all warrants

Key terms include an assumed offering price of $0.9709 per share, with Series A warrants having a 5-year term and Series B warrants an 18-month term. H.C. Wainwright & Co. is acting as exclusive placement agent, receiving a 7% cash fee and 1% management fee. The company, classified as a smaller reporting and emerging growth company, recently completed a 1-for-25 reverse stock split in June 2024. The offering will terminate on July 18, 2025, unless terminated earlier.